Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Thymosin Alpha-1 Side Effects: Withdrawal and Discontinuation Syndrome

By
Published Updated Last reviewed
8 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / Thymosin alpha-1 (thymalfasin); Zadaxin is a brand sold outside the US [1]
  • US status / Not FDA-approved; orphan designations are not approvals [1]
  • FDA adverse-event search / An April 22, 2024 search found zero reports for thymosin alpha-1 [1]
  • Half-life / About 1.8 to 2.6 hours; no accumulation after five daily doses [2][1]
  • Approved outside the US / Italy, India and Hong Kong, for limited uses [1]
  • Compounding status / FDA proposed not adding Ta1 to the pharmacy bulks list; advisory committee voted 4 yes and 17 no [3]

Does Thymosin Alpha-1 Cause Withdrawal Symptoms?

FDA's search of its adverse-event database on April 22, 2024 found zero reports for Ta1 [1]. That zero count does not rule out symptoms after stopping. A passive reporting system cannot establish rates, and a report's existence would not prove the drug caused the event [4].

Ta1 is described as an immune modulator that augments T-cell function [2].

What the Pharmacokinetics Show

Ta1 is a 28-amino-acid peptide. In healthy volunteers, subcutaneous injection produced peak levels at about 0.7 to 2 hours and a half-life of about 1.8 to 2.6 hours. Daily dosing for five days caused no accumulation [2][1]. Those numbers describe fast clearance. They do not describe a withdrawal phase.

What Safety Data Are Available?

Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as infrequent and mild [1]. That is company-linked data.

A 2026 Cochrane review of hepatitis B trials found that Ta1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [5]. A 1991 pilot in 12 people reported no significant side effects [6].

US Regulatory Status in Brief

Thymosin alpha-1 is not FDA-approved, and no US-approved dose exists [1]. It has four US orphan drug designations, but orphan designation is not an approval [1]. Zadaxin is approved in some other countries, including Italy (as an adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults with compensated liver disease and virus replication) and Hong Kong [1].

FDA's page on bulk substances that may raise significant safety risks when compounded lists Ta1 in the "nominated but withdrawn" table; it was formerly in category 2 and came off because the nominators withdrew. FDA's posted concerns include immunogenicity risk for certain routes, peptide impurities and characterization problems, and safety information it called inadequate [7].

What Happens After Treatment Ends in Hepatitis B Trials?

The largest recent synthesis is a 2026 Cochrane review of 10 randomized trials with 1,349 adults. It found possible lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) but rated the certainty very low. It found little to no effect on quality of life or liver histology, and the reviewers said they were not sure Ta1 helps [5].

An older meta-analysis of five trials with 353 patients looked at thymosin treatment lasting over 24 weeks. The virological response increased the further out from the end of treatment it was measured, reaching a significant benefit at 12 months after treatment ended (odds ratio 2.67, 95% CI 1.25 to 5.68) [8]. That finding concerns hepatitis B viral response, not withdrawal symptoms.

What the Italian Label Says

The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. It says the product is not for children and is contraindicated in pregnancy and breastfeeding. It advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

Frequently asked questions

Is there a thymosin alpha-1 withdrawal syndrome?
A withdrawal syndrome has not been documented. FDA's April 22, 2024 adverse-event search returned zero reports for Ta1, but a passive reporting system cannot rule out symptoms after stopping or establish their rate [1][4]. Studies that followed people after treatment measured hepatitis B outcomes, not withdrawal symptoms [8].
What happens after stopping thymosin alpha-1?
Peak levels come at about 0.7 to 2 hours after a subcutaneous dose, with a half-life of about 1.8 to 2.6 hours and no accumulation after five daily doses [2][1]. Those numbers describe fast clearance, not a withdrawal phase. A meta-analysis of thymosin trials in hepatitis B found the virological response increased with time since treatment stopped, with benefit measurable at 12 months (odds ratio 2.67, 95% CI 1.25 to 5.68) [8].
Is thymosin alpha-1 FDA-approved?
No. It has four US orphan drug designations, but orphan designation is not approval. Zadaxin is approved in some other countries, including Italy, India and Hong Kong [1].
Does thymosin alpha-1 cause side effects during treatment?
Authors tied to the manufacturer describe adverse experiences as infrequent and mild across more than 17 million doses of Zadaxin [1]. A 2026 Cochrane review found that Ta1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low certainty) [5].
Can thymosin alpha-1 be tapered?
The Italian Zadaxin label describes fixed courses: 1.6 mg twice weekly for 4 weeks, repeated from week 8 to week 12 at the second vaccination. It does not describe a gradual dose reduction [1].

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8. Thymosin alpha-1
  3. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  4. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA. FDA Adverse Event Monitoring System (AEMS) Public Dashboard | FDA
  5. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610. Thymosin-ɑ1 for people with chronic hepatitis B
  6. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  8. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther. 2001;15(12):1899-905. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis
Evidence overview for Thymosin Alpha-1 Side Effects: Withdrawal and Discontinuation Syndrome